CN109310766A - 多特异性分子 - Google Patents
多特异性分子 Download PDFInfo
- Publication number
- CN109310766A CN109310766A CN201780024999.5A CN201780024999A CN109310766A CN 109310766 A CN109310766 A CN 109310766A CN 201780024999 A CN201780024999 A CN 201780024999A CN 109310766 A CN109310766 A CN 109310766A
- Authority
- CN
- China
- Prior art keywords
- bdm
- molecule
- antibody
- vld
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016900708A AU2016900708A0 (en) | 2016-02-26 | Multi-specific molecules 1 | |
| AU2016900709A AU2016900709A0 (en) | 2016-02-26 | Multi-specific molecules 2 | |
| AU2016900709 | 2016-02-26 | ||
| AU2016900708 | 2016-02-26 | ||
| PCT/AU2017/050168 WO2017143406A1 (en) | 2016-02-26 | 2017-02-27 | Multi-specific molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109310766A true CN109310766A (zh) | 2019-02-05 |
Family
ID=59685848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201780024999.5A Pending CN109310766A (zh) | 2016-02-26 | 2017-02-27 | 多特异性分子 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20190338013A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3419667A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7536424B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109310766A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017222700B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201734037A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017143406A1 (cg-RX-API-DMAC7.html) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113631576A (zh) * | 2019-03-26 | 2021-11-09 | 四十七公司 | 用于治疗癌症的多特异性药剂 |
| CN114981306A (zh) * | 2019-11-04 | 2022-08-30 | 努玛治疗有限公司 | 多特异性抗体 |
| CN115698056A (zh) * | 2020-04-29 | 2023-02-03 | 霍伯生物技术公司 | 双特异性蛋白 |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017222700B2 (en) * | 2016-02-26 | 2018-09-27 | Imunexus Therapeutics Limited | Multi-specific molecules |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| IL270743B2 (en) | 2017-05-19 | 2024-09-01 | Wuxi Biologics Shanghai Co Ltd | Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof |
| KR20210029298A (ko) * | 2017-08-16 | 2021-03-15 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질 |
| SG11202004158QA (en) | 2017-12-28 | 2020-06-29 | Nanjing Legend Biotech Co Ltd | Single-domain antibodies and variants thereof against tigit |
| CN111836832A (zh) * | 2018-01-08 | 2020-10-27 | 南京传奇生物科技有限公司 | 多特异性抗原结合蛋白及其使用方法 |
| CA3084518A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| BR112021012631A2 (pt) | 2018-12-26 | 2021-12-14 | Xilio Dev Inc | Anticorpos anti-ctla4 e métodos de uso dos mesmos |
| US20230002450A1 (en) * | 2019-02-18 | 2023-01-05 | Courier Therapeutics, Inc. | Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner |
| WO2021147857A1 (en) * | 2020-01-20 | 2021-07-29 | Wuxi Biologics (Shanghai) Co., Ltd | A novel wash buffer solution for affinity chromatography |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| WO2022081529A1 (en) * | 2020-10-12 | 2022-04-21 | Greffex, Inc. | Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| US11993657B2 (en) * | 2021-03-16 | 2024-05-28 | Jn Biosciences Llc | Bifunctional molecules for treatment of immune disorders |
| JP2024543164A (ja) * | 2021-11-26 | 2024-11-19 | イミュネクサス・セラピューティクス・リミテッド | 細胞表面上の結合ドメイン分子 |
| CN115078718B (zh) * | 2022-07-22 | 2024-11-12 | 福建师范大学 | 一种基于表面增强拉曼技术检测透明质酸酶的方法 |
| KR20250087648A (ko) * | 2022-11-09 | 2025-06-16 | 리플리겐 코포레이션 | 친화도 제제 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166697B1 (en) * | 1998-03-06 | 2007-01-23 | Diatech Pty. Ltd. | V-like domain binding molecules |
| WO2008096158A2 (en) * | 2007-02-08 | 2008-08-14 | Domantis Limited | Antibody single variable domains against serum albumin |
| WO2010136492A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| CN101932608A (zh) * | 2007-11-30 | 2010-12-29 | 葛兰素集团有限公司 | 抗原结合构建体 |
| CN102227447A (zh) * | 2008-10-02 | 2011-10-26 | 新兴产品开发西雅图有限公司 | Cd86拮抗物多靶点结合蛋白 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000060070A1 (en) * | 1999-04-01 | 2000-10-12 | Innogenetics N.V. | A polypeptide structure for use as a scaffold |
| US20100081792A1 (en) * | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| WO2010136485A1 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
| AU2017222700B2 (en) * | 2016-02-26 | 2018-09-27 | Imunexus Therapeutics Limited | Multi-specific molecules |
| JP2024543164A (ja) * | 2021-11-26 | 2024-11-19 | イミュネクサス・セラピューティクス・リミテッド | 細胞表面上の結合ドメイン分子 |
-
2017
- 2017-02-27 AU AU2017222700A patent/AU2017222700B2/en active Active
- 2017-02-27 JP JP2018563747A patent/JP7536424B2/ja active Active
- 2017-02-27 CN CN201780024999.5A patent/CN109310766A/zh active Pending
- 2017-02-27 WO PCT/AU2017/050168 patent/WO2017143406A1/en not_active Ceased
- 2017-02-27 US US16/079,949 patent/US20190338013A1/en not_active Abandoned
- 2017-02-27 EP EP17755659.4A patent/EP3419667A4/en active Pending
- 2017-03-01 TW TW106106646A patent/TW201734037A/zh unknown
-
2019
- 2019-01-02 AU AU2019200005A patent/AU2019200005A1/en not_active Abandoned
-
2020
- 2020-06-22 US US16/946,451 patent/US20210040177A1/en not_active Abandoned
-
2021
- 2021-04-06 US US17/223,935 patent/US11345736B2/en active Active
-
2022
- 2022-05-11 JP JP2022078237A patent/JP2022105574A/ja active Pending
-
2023
- 2023-08-28 US US18/239,052 patent/US20240182542A1/en active Pending
- 2023-12-26 JP JP2023219531A patent/JP7857274B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166697B1 (en) * | 1998-03-06 | 2007-01-23 | Diatech Pty. Ltd. | V-like domain binding molecules |
| WO2008096158A2 (en) * | 2007-02-08 | 2008-08-14 | Domantis Limited | Antibody single variable domains against serum albumin |
| CN101932608A (zh) * | 2007-11-30 | 2010-12-29 | 葛兰素集团有限公司 | 抗原结合构建体 |
| CN102227447A (zh) * | 2008-10-02 | 2011-10-26 | 新兴产品开发西雅图有限公司 | Cd86拮抗物多靶点结合蛋白 |
| WO2010136492A2 (en) * | 2009-05-28 | 2010-12-02 | Glaxo Group Limited | Antigen-binding proteins |
Non-Patent Citations (2)
| Title |
|---|
| NUTTALL SD等: "Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides", 《PROTEINS》 * |
| SIMON E.HUFTONA等: "Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands", 《FEBS LETTERS》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113631576A (zh) * | 2019-03-26 | 2021-11-09 | 四十七公司 | 用于治疗癌症的多特异性药剂 |
| CN114981306A (zh) * | 2019-11-04 | 2022-08-30 | 努玛治疗有限公司 | 多特异性抗体 |
| CN115698056A (zh) * | 2020-04-29 | 2023-02-03 | 霍伯生物技术公司 | 双特异性蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019200005A1 (en) | 2019-01-24 |
| AU2017222700B2 (en) | 2018-09-27 |
| US20210230249A1 (en) | 2021-07-29 |
| EP3419667A1 (en) | 2019-01-02 |
| JP2024026531A (ja) | 2024-02-28 |
| JP7857274B2 (ja) | 2026-05-12 |
| JP2022105574A (ja) | 2022-07-14 |
| US20190338013A1 (en) | 2019-11-07 |
| TW201734037A (zh) | 2017-10-01 |
| JP7536424B2 (ja) | 2024-08-20 |
| WO2017143406A1 (en) | 2017-08-31 |
| US20240182542A1 (en) | 2024-06-06 |
| US20210040177A1 (en) | 2021-02-11 |
| JP2019510812A (ja) | 2019-04-18 |
| EP3419667A4 (en) | 2019-10-23 |
| US11345736B2 (en) | 2022-05-31 |
| AU2017222700A1 (en) | 2018-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240182542A1 (en) | Multi-Specific Molecules | |
| CN114729041B (zh) | 用于治疗多种实体瘤的靶向b7h3(cd276)的高亲和力纳米抗体 | |
| CN106999587B (zh) | 多价中间表位,中间表位结合抗体及其用途 | |
| EP4582449A1 (en) | Recombinant humanized monoclonal antibody targeting human gprc5d and application thereof | |
| CN109311979A (zh) | Psma和cd3双特异性t细胞接合抗体构建体 | |
| CN105777907A (zh) | 叶酸受体1抗体与免疫缀合物以及其用途 | |
| JP7056858B2 (ja) | 新規な組換え型二機能性融合タンパク質、その調製方法および用途 | |
| CN102482347A (zh) | 修饰抗体组合物及其制备和使用方法 | |
| US11912771B2 (en) | MAGE-A4 peptide-MHC antigen binding proteins | |
| US20260110113A1 (en) | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same | |
| JP2021532778A (ja) | Psmaに対するヒト化抗体 | |
| JP2002517223A (ja) | モノクローナル抗体、交叉反応性抗体およびそれを生成する方法 | |
| CN117964767B (zh) | 抗rage抗体、细胞外囊泡及其制备方法和应用 | |
| JP2024100838A (ja) | 抗ラムダ骨髄腫抗原(lma)発現がん及び自己免疫障害を処置するlma結合タンパク質 | |
| Guo et al. | HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity | |
| WO2023045370A1 (zh) | 靶向tigit的单克隆抗体 | |
| CN111548417B (zh) | EGFRvIII和EGFR的双特异性人源抗体及其应用 | |
| JP2023548345A (ja) | クリッピング率の低減した抗原結合ドメイン | |
| WO2024123708A1 (en) | Broadly neutralizing antibody-templated divalent immunogen vaccines | |
| CN117751146A (zh) | Mage-a4肽-mhc抗原结合蛋白 | |
| CN117285628A (zh) | 抗vista抗体及其应用 | |
| CN118725130A (zh) | 抗ctla-4/抗tigit双特异性抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210621 Address after: Victoria, Australia Applicant after: Imonius treatment Ltd. Address before: Victoria, Australia Applicant before: Imunexus Pty Ltd. |
|
| TA01 | Transfer of patent application right |